Glutarimide: A carrier transport drug through cell membranes

Medical Hypotheses

Volumn 54, Issue 3, 2000, Pages 472-474

  Michalska, D ^a   Morzyk, B ^a   Bienko, D C ^a   Wojciechowski, W ^a  

^a WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTARIMIDE; NUCLEOSIDE; THYMINE; URACIL; DRUG CARRIER; PIPERIDONE DERIVATIVE;

CALCULATION; CELL MEMBRANE; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; HUMAN; MEMBRANE TRANSPORT; PRIORITY JOURNAL; SHORT SURVEY; ARTICLE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; CELL MEMBRANE; DRUG CARRIERS; PIPERIDONES;

EID: 0033625108     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0879     Document Type: Article

References (20)

1. Bottger E. C., Blanar M. A., Flavell R. A. Cycloheximide, an inhibitor of protein synthesis, prevents gamma-interferon induced expression of class-II messenger-RNA in a macrophage cell line. Immunogenetics. 28:1988;215-220.
2. Grollman A. P. Structural basis for inhibition of protein synthesis by emetine and cycloheximide based on an analogy between Ipecac alkaloids and glutamine antibiotics. Proc Natl Acad Sci USA. 56:1966;1867-1874.
3. Osada H., Sonoda T., Kusakabe H., Isono K. Epiderstatin, a new inhibitor of the mitogenic activity induced by epidermal growth factor. J Antibiotics. 42:1989;1599-1606.
4. Matsuda F., Kawasaki M., Terashima S. Efficient synthesis and antitumor activity of an enantiomeric pair of the sesbanimide AB-ring systems. Tetrahedron Lett. 26:1985;4639-4642.
5. Gale K. E. Treatment of advanced breast cancer with aminoglutethimide. Cancer Res Suppl. 42:1982;3389-3396.
6. Burzynski S. R. Antineoplastons: biochemical defense against cancer. Physiol Chem Phys. 8:1976;275-279.
7. Hendry L. B., Muldoon T. G. Actions of an endogenous antitumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA. J Steroid Biochem. 30:1988;325-328.
8. Laycock G. M., Shulman A. Partial agonists in the central nervous system. Nature. 200:1963;849-851.
9. Stephens T. D. Proposed mechanisms of action in thalidomide embryopathy. Teratology. 38:1988;229-239.
10. Schuler U., Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Saf. 12:1995;364-369.
11. Wood P. M., Proctor S. J. The potential use of thalidomide in the therapy of graft-versus-host disease: a review of clinical and laboratory information. Leuk Res. 14:1990;395-399.
12. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety consideration. Drug Saf. 7:1992;116-134.
13. Makonkawkeyoon S., Limson-Pobre R. N., Moreira A. L., Schauf V., Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 90:1993;5974-5978.
14. Michalska D. MNDO Studies on the structure of Antineoplaston A10, glutarimide and piperidine. J Mol Struct (Theochem). 231:1991;357-366.
15. Bienko D. C., Michalska D., Roszak S., Wojciechowski W., Nowak M. J., Lapinski L. Infrared matrix isolation and theoretical studies on glutarimide. J Phys Chem A. 101:1997;7834-7841.
16. Michalska D. The Raman and IR spectra and normal coordinate analysis of 3-(N-phenylacetylamino)-2,6- piperidinedione, Antineoplaston A10, the new antitumour drug. Spectrochim. Acta. 49A:1993;303-314.
17. Morzyk B., Michalska D., Wojciechowski W. Interaction of metal ions with 3,3-dimethylglutarimide. J Coord Chem. 34:1995;179-185.
18. Michalska D., Morzyk B., Wojciechowski W. A potentiometric study of metal ion complexes of Antineoplaston A10, a new antitumour agent. J Coord Chem. 38:1996;101-106.
19. Michalska D., Morzyk B., Wojciechowski W., Glowiak T. Two novel complexes of glutarimide with palladium(II). Inorg Chim Acta. 248:1996;159-166.
20. Morzyk, B. Michalska, D. Wojciechowski, W. Glowiak, T. Molecular structure of the novel mercury(II) complex with 3,3-dimethylglutarimide. J Mol Struct.